Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR58611A + Escitalopram in MDD
NCT00432614Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2007
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of amibegron in major depressive disorder (MDD) (3 arms), sponsored by Sanofi. Primary endpoint: Hamilton Depression Rating Scale at 8 weeks. Started Jan 2007; status: completed.
02
Drugs
amibegron
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00432614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00432614.